Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes

BACKGROUND: Liraglutide was first released in Japan as a long-acting once-daily glucagon-like peptide-1 receptor agonist. The maximum dose in Japan is 0.9 mg/day, which is half of that used in the United States and the European Union (1.8 mg/day). The efficacy of this maximum allowable dose of lirag...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Daisuke, Iuchi, Takujiro, Kurihara, Susumu, Inoue, Ikuo, Katayama, Shigehiro, Inukai, Kouichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522987/
https://www.ncbi.nlm.nih.gov/pubmed/26251684
http://dx.doi.org/10.14740/jocmr2237w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522987/
https://www.ncbi.nlm.nih.gov/pubmed/26251684
http://dx.doi.org/10.14740/jocmr2237w

Ejemplares similares